This verifies that the secondary ECL1/2 epitope and Fab ... Structure of CD20 in complex with the therapeutic monoclonal antibody RTX. Image Credit: Lionel Rougé, et al., Science, 2020 To support ...

GB261 combines the well-established anti-CD20 cancer drug rituximab with an anti-CD3 antibody arm ... Using CAAD and epitope binning, multiple VHHs binding to different predicted epitopes on ...

Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s Keymed ...

Rituximab detects CD20 not only at its primary epitope ... Rituximab’s CDC activity is affected by this secondary epitope. To properly evaluate antibody activity and mode of action, full-length ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

Researchers identified that the dominant B cell epitope of Lachnospiraceae flagellins and the utilization of the flagellin ...

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. The company said it expects fourth-quarter BRIUMVI net product revenue in the U.S. to be $103.6 ...

About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to assess the safety, tolerability ...